HIF1A and cancer: This approach, combined with the potential of combination therapies involving CDK and HSP-90 inhibitors, could significantly impact cancer progression and drug resistance by stabilizing HIF1α, suggesting a synergistic mechanism that broadens the scope of combating therapy resistance (1, 75).